Cog-Pro

Impact of hormone-therapy of new generations on elderly patient cognitive functions treated for a metastatic prostate cancer

Coordinator: Florence Joly

Context: New hormonotherapy targeting the androgenic axis are used in metastatic prostate cancer patients resistant to castration. Even if these treatments have demonstrated a clear beneficial impact on the global survival, their effects on cognitive functions have never been tested while cognitive troubles would affect the observance and the autonomy of elderly patients.

Objective: To evaluate the occurrence of cognitive deficits and the cognitive complaint of elderly patients treated by a new generation hormonotherapy (Abiraterone acetate or enzalutamide) for a metastatic prostate cancer resistant to castration.

Study methodology: Non-randomized, longitudinal study, multicentric comparing a group of patients of interest (134), a control patient group (55) and a group of healthy volunteers (33)

Study status: Open to inclusions, 151 participants included so far

Collaboration: 7 participating centers

Financial support: INCA and ASTELLAS

Publications:

Lange M, Laviec H, Castel H, Heutte N, Leconte A, Leger I, et al. Impact of new generation hormone-therapy on cognitive function in elderly patients treated for a metastatic prostate cancer: Cog-Pro trial protocol. BMC Cancer. 2017;17(1):549.

Lange M, Laviec H, Castel H, Heutte N, Leconte A, Léger I, Giffard B, Capel A, Dubois M, Clarisse B, Coquan E, Di Fiore F, Gouérant S, Bartélémy P, Pierard L, Fizazi K, Joly F. Correction to: Impact of new generation hormone-therapy on cognitive function in elderly patients treated for a metastatic prostate cancer: Cog-Pro trial protocol. BMC Cancer. 2018 Jan 30;18(1):110. doi: 10.1186/s12885-017-3764-9. PubMed PMID: 29382311; PubMed Central PMCID: PMC5791194.